The landmark IMpower133 [6] and CASPIAN [7] studies indicated that first‐line anti‐PD‐L1 atezolizumab or durvalumab in combination with CT significantly prolonged OS in patients with ES‐SCLC compared to CT alone. Here, CD274 is linked to small cell lung carcinoma.